Senator Ron Johnson, R-Wisconsin, wrote FDA Commissioner Scott Gottlieb, MD, to make clear the intent of the federal “right-to-try” law he authored; the number of opioid prescriptions has fallen by 22% between 2013 and 2017; inadequate record-keeping, policy gaps and limited research are leaving military veterans in limbo and struggling to get care from the Department of Veterans Affairs if their claims for brain injuries are related to the use of weapons in training instead of in combat.
Senator Ron Johnson, R-Wisconsin, wrote FDA Commissioner Scott Gottlieb, MD, Thursday to make clear the intent of the federal “right-to-try” law he authored, according to STAT. “This law intends to diminish the FDA’s power over people’s lives, not increase it,” he wrote in a letter to Gottlieb following President Trump signing the law this week. Johnson requested a meeting about the implementation of the law. Gottlieb said in an interview with STAT last month that the FDA could still protect patients through the regulatory process; the new law allows patients with life-threatening illnesses to request access to experimental therapies the agency hasn’t approved.
The number of opioid prescriptions has fallen by 22% between 2013 and 2017, according to a report from the American Medical Association. The Hill reported it’s the fifth year in a row that prescriptions have dropped. Between 2016 and 2017, there was a 121% increase in doctors accessing electronic databases that track opioid prescribing. And, as of May, the number of doctors certified to provide buprenorphine rose 42% in the last 12 months.
Inadequate record keeping, policy gaps and limited research are leaving military veterans in limbo and struggling to get care from the Department of Veterans Affairs if their claims for brain injuries are related to the use of weapons in training instead of in combat, The Wall Street Journal reported. The military doesn’t don’t record when or how many rockets are fired in training, leaving veterans without the proof they need of how they were injured.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More